Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Bone Microarchitecture Evaluation by HR-pQCT in Youngs Who Developed AN in Peri or Prepubertal Period. (AMOS)

Monocentric Study Evaluating Bone Microarchitecture by High Resolution Quantitative Computerized Tomography (HR-pQCT) in Young Adults and Adolescents Who Developed Anorexia Nervosa (AN) in Peri or Prepubertal Period.

The occurrence of anorexia nervosa (AN) during childhood or adolescence rapidly induces starvation, stop of growth and impaired mineralization of bone tissue together with an interruption of pubertal development. These consequences are initially reversible following food intake return but can lead to a more irreversible status with low height, osteoporosis and high fracture risk. The onset of the disease more and more early in life, with the first stages of puberty suggest that these consequences will be even more severe as bone resistance will be damaged by more profound effects on bone growth as well. It is therefore critical to evaluate these bone metabolism alterations in order to better manage these patients.

At every age and in every clinical circumstance either physiologic or pathologic, high resolution peripheral quantitative computerized tomography (HRpQCT) provides an evaluation of bone microarchitecture that is more informative than the global quantitative assessment given by conventional Dual Energy X-ray Absorptiometry) DEXA, with a better estimate of clinical fracture risk.

Here, we propose to measure cortical parameters, such as cortical thickness which plays a key role in bone biomechanical strength in young adults aged between 20 and 30 years-old, who had developed AN as early as the during the first stages of puberty but no longer present, compared to age-and sex-matched healthy volunteers. Other micro-architectural parameters will also be studied. In an exploratory phase, we will evaluate these bone microarchitectural parameters together with bone biological turnover markers and markers of sexual maturation in adolescents or young adults 20 years-old or less, undernourished and currently managed for AN.

Studieoversikt

Status

Fullført

Forhold

Studietype

Intervensjonell

Registrering (Faktiske)

34

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Saint-etienne, Frankrike, 42000
        • CHU de Saint-Etienne

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

10 år til 30 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients over 20 years old:

    • Age > 20 and < 30 years old
    • Patients managed for AN in the pediatric or endocrinology of the university hospital of St-Etienne
    • Patients who developed AN as early as the during the first stages of puberty defined by Tanner stage 1 to 4, with a diagnosis of AN based on DSM-IV current criteria:
    • Weight loss : deny of maintaining body weight over minimal normal threshold (85 % age and height matched)
    • Intense fear of gaining weight or becoming obese despite weight insufficiency;
    • Impaired perception of weight or dysmorphophobia;
    • Excessive role of weight or body shape in self-esteem or deny of current leanness;
    • Secondary amenorrhea during 3 or more menstrual cycles in young girls or primary amenorrhea
    • Duration of AN of at least 6 months
    • BMI >85% of theoretical BMI (efficient renutrition)
  • Patients less than 20 years old :

    • Age > 10 and < 20 years old
    • Patients managed for AN in the pediatric or endocrinology of the university hospital of St-Etienne
    • Patients who developed AN as early as the during the first stages of puberty defined by Tanner stage 1 to 4, with a diagnosis of AN based on DSM-IV current criteria:
    • Weight loss : deny of maintaining body weight over minimal normal threshold (85 % age and height matched)
    • Intense fear of gaining weight or becoming obese despite weight insufficiency;
    • Impaired perception of weight or dysmorphophobia;
    • Excessive role of weight or body shape in self-esteem or deny of current leanness;
    • Secondary amenorrhea during 3 or more menstrual cycles in young girls or primary amenorrhea
    • Duration of AN of at least 6 months

Exclusion Criteria:

  • Renal insufficiency
  • Cushing
  • Dysthyroidism
  • Inflammatory disease
  • Pregnancy
  • Lack of consent
  • Subject under legal protection

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Patients 20 - 30 years-old
HR-pQCT and DEXA for measure bone quality and quantity
The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
Andre navn:
  • Xtrem CT scanco
The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
Eksperimentell: Patients 10 - 20 years-old
Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
Andre navn:
  • Xtrem CT scanco
The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cortical thickness
Tidsramme: Day 1
Cortical thickness (in mm) is a composite outcome measured with HR pQCTon 3D images of distal radius and distal tibia.
Day 1

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of patients with bone degradation
Tidsramme: Day 1
Bone degradation is a composite outcome measured by cortical and architectural parameters measured with HR pQCTon 3D images of distal radius and distal tibia. The parameters are : Total volumetric bone mineral density (mg/ccm HA), Trabecular volumetric bone mineral density (mg/ccm HA), Cortical volumetric bone mineral density (mg/ccm HA), Number of bone trabeculae (1/mm), Trabecular thickness (mm) Cortical thickness (mm), Trabecular spacing (mm), Trabecular distribution (mm)
Day 1
number of patients with osteoporosis
Tidsramme: Day 1
Osteoporosis is measured with DEXA. DEXA measure the Bone Mineral Density (g/cm2)
Day 1
Clinical and biological phenotype of AN patients 20 years-old or less
Tidsramme: Day 1
Clinical and biological phenotype of AN patients 20 years-old or less is a composite factor : Pubertal stage at disease onset, Duration of AN, Height shortening compared to optimal genetically defined height, Serum levels of FGF23, Serum levels of IGF 1, Serum levels of sexual steroids (FSH, LH, oestradiol, testosterone, SeBG, AMH, inhibin B), Serum levels of bone formation and resorption markers (cross laps, osteocalcin, total alkaline phosphatases), Serum levels of leptin, Bone mineral density measured by DXA
Day 1

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Thierry THOMAS, MD PhD, CHU de Saint-Etienne

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. november 2015

Primær fullføring (Faktiske)

29. november 2017

Studiet fullført (Faktiske)

29. november 2017

Datoer for studieregistrering

Først innsendt

17. august 2015

Først innsendt som oppfylte QC-kriteriene

17. august 2015

Først lagt ut (Anslag)

18. august 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. februar 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. februar 2018

Sist bekreftet

1. februar 2018

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 1408082
  • 2015-A00100-49 (Annen identifikator: ANSM)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere